ADMA Biologics (ADMA) Competitors

ADMA Biologics (NASDAQ:ADMA) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Do analysts prefer ADMA or SLDB?

ADMA Biologics currently has a consensus price target of $15.50, suggesting a potential downside of 23.61%. Solid Biosciences has a consensus price target of $15.67, suggesting a potential upside of 138.10%. Given Solid Biosciences' higher probable upside, analysts plainly believe Solid Biosciences is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Do institutionals and insiders believe in ADMA or SLDB?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by company insiders. Comparatively, 13.6% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media refer more to ADMA or SLDB?

In the previous week, ADMA Biologics had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for ADMA Biologics and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.20 beat ADMA Biologics' score of 0.82 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor ADMA or SLDB?

ADMA Biologics received 149 more outperform votes than Solid Biosciences when rated by MarketBeat users. Likewise, 71.93% of users gave ADMA Biologics an outperform vote while only 68.15% of users gave Solid Biosciences an outperform vote.

Company	Underperform	Outperform
ADMA Biologics	Outperform Votes 410 71.93%	Underperform Votes 160 28.07%
Solid Biosciences	Outperform Votes 261 68.15%	Underperform Votes 122 31.85%

Which has more risk and volatility, ADMA or SLDB?

ADMA Biologics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Which has higher valuation and earnings, ADMA or SLDB?

ADMA Biologics has higher revenue and earnings than Solid Biosciences. ADMA Biologics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$330.24M	14.24	-$28.24M	-$0.02	-1,014.50
Solid Biosciences	$8.09M	31.40	-$96.01M	-$3.94	-1.67

Is ADMA or SLDB more profitable?

ADMA Biologics has a net margin of 10.53% compared to Solid Biosciences' net margin of 0.00%. ADMA Biologics' return on equity of 38.79% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	10.53%	38.79%	17.35%
Solid Biosciences	N/A	-53.76%	-43.74%

Summary

ADMA Biologics and Solid Biosciences tied by winning 9 of the 18 factors compared between the two stocks.